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Abstract
Introduction: With improved survival, adolescents with perinatal HIV (PHIV) are transitioning from paediatric to adult care,
but there are few published data on clinical outcomes post-transfer. Using linked data from patients in the national UK/
Ireland paediatric cohort (CHIPS) and an adult UK cohort of outpatient clinics (UK CHIC), we describe mortality and changes
in immunological status post-transfer.
Methods: Participants in CHIPS aged ≥13 years by the end of 2013 were linked to the UK CHIC database. Mixed effects
models explored changes in CD4 count before and after transfer, including interactions between time and variables where
interaction p < 0.05.
Results: Of 1,215 paediatric participants aged ≥13 years, 271 (22%) had linked data in UK CHIC. One hundred and forty-six
(53%) were female, median age at last visit in paediatric care was 17 [interquartile range, IQR 16,18] years, median duration
in paediatric care was 11.8 [6.6,15.5] years, and in adult care was 2.9 [1.5,5.9] years. At last visit in paediatric care, 74%
(n = 200) were on ART, increasing to 84% (n = 228, p = 0.001) at last visit in adult care. In the 12 months before leaving
paediatric care, 92 (47%) had two consecutive viral loads >400 copies/mL or one viral load >10,000 copies/mL, and likewise
102 (52%) in the 12 months post-transfer (p = 0.79). Seven (3%) people died in adult care. In multivariable analysis, CD4
declined as patients approached transition with a greater decline in those with higher nadir CD4 count (mean rates of decline
of 3, 13, 15, 30 cells/mm3 per year for those with nadir CD4 < 100, 100–199, 200–299 and ≥300 cells/mm3, respectively).
Post-transition, CD4 continued to decline in some groups (e.g. black males, −20 (−34, −5) cells/mm3 per year post transition,
p = 0.007)) while it improved in others. Overall CD4 was higher with later year of birth (14 (7, 21) cells/mm3 per later year).
There was no effect of age at transfer or changing hospital at transfer on CD4.
Conclusions: Our findings suggest that CD4 in adolescents with perinatal HIV in the UK was declining in the period before
transition to adult care, and there was some reversal in this trend post-transfer in some groups. Across the transition period,
CD4 was higher in those with later birth years, suggesting improvements in clinical care and/or transition planning over time.
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Introduction
Adolescence is recognized as a critical period for developing
patterns of self-management and laying the foundations for
good health in adulthood. The rapid biological and psycho-
social changes that take place during this period affect
every aspect of the lives of adolescents [1], and thus it is
an important stage at which to deliver supportive health-
care services. However, many studies have shown that
health outcomes for chronic conditions are worse in ado-
lescents than in children or adults; these poorer outcomes
appear to be linked to poorly planned transition from
paediatric to adult care [2–9]. This issue is pertinent to
perinatal HIV, as around 1.8 million children were living
with HIV globally in 2015 [10], and children are entering
adulthood in increasing numbers. To date, few studies have
investigated the effect of transition from paediatric to adult
care on health outcomes in the field of HIV.
Emerging data suggest high mortality and morbidity in
adolescents with perinatal HIV [11]. The World Health
Organization reported that HIV had become the eighth
leading cause of death for all adolescents worldwide by
2012 [12], and the fourth leading cause of disability-
adjusted life-years lost, with broadly equal impact across
males and females [1]. These findings were consistent with
the Global Burden of Disease (GBD) Study which showed
that HIV rose from the 101st cause of adolescent disability-
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adjusted life-years lost in 1990 to the 6th highest cause in
2013 [13]. Findings from the USA have described alarmingly
poorer outcomes among adolescents generally, compared
to older adults, at every step of the treatment cascade,
with one study suggesting that only a third of young people
with perinatal or horizontal HIV receiving HIV care in the
USA were virologically suppressed [14,15]. The HIV
Research Network based in the USA reported that 20% of
youth aged 21 years receiving HIV care were lost to follow-
up within one year [16]. In the UK and Europe, studies of
young people with perinatal HIV suggest similarly poor
outcomes, with increased risk of mortality [17], care disen-
gagement [18], and treatment failure [19,20].
Paediatric HIV is a rare disease in the UK and Ireland, but
people with perinatal HIV comprise one of the most mature
national cohorts of adolescent and adult survivors globally
[21]. By the end of 2014, 1,907 children with HIV living in
the UK and Ireland had been followed through the
Collaborative HIV Paediatric Study (CHIPS) cohort, of
whom 644 (34%) had moved to adult care. Transition to
adult care generally does not happen at a defined time
point in the UK; rather, it is tailored to the individual and
their specific needs [22]. Young people move from approxi-
mately 60 paediatric outpatient clinics across the UK to
adult care, with some adult clinics having “adolescent-
friendly” services. The UK has guidelines on transition,
both for chronic diseases generally and also specifically
for HIV [22,23], but it is not clear if they have led to
improvements in health outcomes.
Few studies are able to directly observe patients across
the paediatric and adult care pathway and compare out-
comes pre- and post-transition. In this study, we linked
individual patient data for children and young people with
perinatal HIV across two cohorts, the national CHIPS pae-
diatric cohort, and the UK Collaborative HIV Cohort Study
(UK CHIC), a large adult cohort of outpatient clinic atten-
ders. We describe mortality, antiretroviral treatment (ART),
CD4 and viral load status pre- and post-transfer and, for the
first time in a transition study, model CD4 change over the
transition period and investigate predictors of change pre-
and post-transition.
Methods
The CHIPS and UK CHIC cohorts have been described else-
where [24,25]. In brief, the National Study of HIV in
Pregnancy and Childhood (NSHPC) collects reports of all
infants born to HIV-infected women and all children aged
<16 years diagnosed with HIV infection (regardless of coun-
try of birth) in the UK and Ireland. Subsequent follow-up
information is collected annually through CHIPS, and ceases
when a person transfers from paediatric to adult care,
which happens at median of 17 years of age [26]. Patients
transferring to adult care can choose the adult clinic which
they wish to attend, although most paediatric clinics have a
“partner” adult clinic which is usually the default choice for
a patient. UK CHIC is a multicentre cohort of HIV-positive
adults aged ≥16 years attending one of 21 collaborating
adult outpatient clinics across the UK. Participating UK CHIC
clinics each submit a dataset of routinely collected clinical
information (including basic demographics, CD4 counts,
viral loads, ART use, clinical outcomes and laboratory mar-
kers of ART toxicity and comorbidities) annually; these
datasets are collated across study sites to form the study
database. Both studies have National Health Service (NHS)
Research Ethics approval.
Records of children and young people participating in
CHIPS aged ≥13 years by the end of 2013 who were docu-
mented as having transferred to adult care were linked to
records in the UK CHIC database, using date of birth, initials
and sex, and subjected to further checks across a broader
range of fields (e.g. ethnicity, clinic and Soundex (an index-
ing system which encodes surnames)) for confirmation. The
last date in paediatric care was defined as the last date of a
visit, laboratory marker or ART change in a paediatric clinic,
and the first date in adult care was defined similarly. The
following key outcomes in paediatric compared to adult
care were compared: (i) proportion of the sample pre-
scribed ART at last follow-up visit in paediatric and adult
care; (ii) median CD4 count at 12 months pre- and post-
transfer (individual 12 month pre- and post-CD4s were
defined as the measures taken nearest to but within
±6 months of these time points); (iii) proportion with
CD4 < 200 cells/mm3 at least once in the 12-month periods
pre- and post-transfer; (iv) proportion with two consecutive
viral loads (≤6 months apart) >400 copies/mL or one viral
load >10,000 copies/mL in the 12 month periods pre- and
post-transfer in those on ART for ≥6 months; and (v) pro-
portion with two consecutive viral loads (≤6 months apart)
>400 copies/mL or one viral load >10,000 copies/mL in the
12-month periods pre- and post-transfer (no ART criterion).
Wilcoxon matched-pairs signed-ranks and McNemar’s tests
compared medians and proportions, respectively. All ana-
lyses were conducted using STATA version 14 (College
Station, Texas, USA).
Deaths in adult care were also described. The UK CHIC
Study obtains information on deaths through clinic report-
ing and through linkage to Public Health England’s national
HIV surveillance datasets. These surveillance datasets have
good ascertainment of mortality as they are supplemented
by the Office for National Statistics mortality registry for
deaths occurring under the age of 65, as well as relying on
clinician reporting.
Changes over time in CD4 count before and after transfer
to adult care were explored using mixed effects models,
allowing for multiple measures per person (including all
available data, assuming that the model was robust to
gaps between measures). The transfer date was defined
as the last date in paediatric care. Gaps between the end
of paediatric and the beginning of adult care were
described but in the model were included in adult care.
Time before and after transfer was modelled as a linear
spline with one knot at transfer where time was set to zero.
Years before and after transfer were both categorized as
positive numbers around zero (e.g. 1 year pre-transition
was categorized as +1, as was 1 year post-transition),
to avoid having to present the results of negative main
effects coefficients combined with negative interaction
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coefficients. Person-level random effects were included for
intercept and slopes before and after transfer (unstructured
covariance matrix). Models were adjusted for demographic
characteristics (sex, ethnicity, born abroad, year of birth),
nadir CD4 cell count in paediatric care, and suppressed viral
load <400 copies/mL (yes/no/missing) within 6 months of
the CD4 measurement, and time before/after transfer.
Interactions between time and other variables, including
age at transfer out of paediatric care, and change of hospi-
tal at transfer, were included if the interaction p < 0.05. In a
sensitivity analysis, we included an indicator for time since
previous CD4 (<1 year versus ≥1 year).
Results
Of 701 CHIPS participants aged ≥13 years by the end of
2013 who had transferred to adult care, 271 (39%) were
linked to a corresponding UK CHIC record. Characteristics of
the 271 patients in both datasets are presented in Table 1.
A total of 146 (53%) were female, nearly all were recorded
in CHIPS as having perinatal HIV (93%), 80% had black
ethnicity (of whom 99% were black African) and three-fifths
(61%) were born outside the UK or Ireland, for whom
median age at presentation in the UK was 9 years [inter-
quartile range (IQR) 4, 12] years. Median age at last visit in
paediatric care was 17 [16,18] years, and median age at last
follow-up in adult care was 20 [19,23] years. The median
duration of follow-up in paediatric care was 11.8 [6.6, 15.5]
years. The median gap between last paediatric care visit
and first adult UK CHIC clinic visit was 2.4 [1.0, 4.4] months
(17 people had a gap of ≥12 months), and median duration
of follow-up in adult care was 2.9 [1.5, 5.9] years, giving a
median total duration of follow-up in HIV care of 15.4 [10.6,
19.3] years. Patients had median 3.0 [2.3, 3.8] CD4s and 2.9
[2.0, 3.6] viral loads per year in paediatric follow-up; and
3.4 [2.6, 4.0] viral loads and 3.2 [2.3, 4.6] CD4s per year in
adult follow-up. At last follow-up, 86 (32%) patients had
Centers for Disease Control and Prevention (CDC) Class C
(AIDS defining) diagnosis [27], of whom 9 had their first
CDC C event in adult care.
Seven people (3%) died in adult care, at median age 20
[19,22] years. Six of these seven had a previous CDC C
event, and of these two had their first event in adult care.
Six of the seven were born outside of the UK. Causes of
death were advanced HIV (n = 3), leukoencephalopathy
(n = 1), renal failure (n = 1) and pulmonary tuberculosis
(n = 1), and one unknown cause of death. Figure 1 presents
the individual viral load and CD4 count trajectories for
these seven patients, including periods where ART was
not prescribed. The CD4/viral load trajectories of the
seven were similar, with all experiencing CD4 decline and
increasing viral load prior to death; five of the seven also
had periods when they were not receiving ART prior to
death according to clinic records. Most of these seven
continued to access care fairly regularly after transition,
with a median of 10 viral loads and 9 CD4 cell count
measurements between transition and death, over a med-
ian of 3 years post-transition.
Table 2 presents key outcomes pre- and post-transfer to
adult care. At last visit in paediatric care, 200 (74%) people
were on ART, with this number increasing to 228 (84%,
p = 0.001) at last follow-up in adult care. Median CD4 counts
12 months prior to leaving paediatric care and 12 months
after starting adult care were 465 [288, 668] cells/mm3 and
460 [290, 670] cells/mm3, respectively (p = 0.38). In the
12 months before leaving paediatric care, 21% had at least
one CD4 count <200 cells/mm3, and 23% (p = 0.39) in the
12 months after starting adult care. Among those prescribed
ART for at least six months, 28% and 29% (p = 0.85) had
confirmed viremia >400 copies/mL or one viral load >10,000
copies/mL in the 12 months pre- and post-transfer, respec-
tively. When including all patients, irrespective of ART status,
47% and 52% had confirmed viremia >400 copies/mL or one
viral load >10,000 copies/mL in each period respectively
(p = 0.12). There were no significant differences in key char-
acteristics (including sex, black ethnicity, born outside UK,
ever taken ART, age started ART) between those with CD4/
Table 1. Characteristics of CHIPS participants with perinatal
HIV transitioning to adulthood in the UK and with linked data
in the UK CHIC cohort (n = 271)
n (%) /median
[IQR]
Sex (female) 146 (53%)
Perinatal HIV infectiona 251 (93%)
Ethnicity
Black 213 (80%)
White 28 (11%)
Other 25 (9%)
Born outside UK/Ireland 163 (61%)
Year of birth
Up to 1989 75 (28%)
1990–1994 160 (59%)
1995–1997 36 (13%)
Ever taken ART 246 (91%)
Age started ART 9.8 [5.9, 13.1]
Age at last paediatric care visit (years) 17 [16,18]
Age at last follow up in adult care (years) 20 [19,23]
Duration of paediatric care follow up (years) 11.8 [6.6,15.5]
Duration of adult care follow up (years) 2.9 [1.5,5.9]
Gap between paediatric and adult care
(months)
2.4 [1.0,4.4]
Duration of total follow up (years) 15.4 [10.6,19.3]
Changed hospital at transfer 129 (48%)
Nadir CD4 cell count in paediatric care 194 [90, 281]
Ever CDC Class C (AIDS) diagnosisb 86 (32%)
CHIPS, Collaborative HIV Paediatric Study; UK CHIC, United Kingdom
Collaborative HIV Cohort Study; IQR, interquartile range; ART, antire-
troviral therapy; CDC, Centers for Disease Control and Prevention
aFor the rest, 8 blood transfusion, 12 unknown.
b77 had first AIDS event in paediatric care.
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VL outcomes in both paediatric and adult care and those with
missing data (data not shown).
Univariable and multivariable predictors of change in
CD4 count over time are shown in Table 3. In the multi-
variable model, CD4 was higher (pre- and post-transition)
in those with higher nadir CD4. However, there was a
decline in CD4 as patients approached transition, with a
greater decline in those with higher nadir CD4 (mean
declines of 3, 13, 15, 30 cells/mm3 per year prior to
transfer for those with nadir CD4 <100, 100–199,
200–299 and ≥300 cells/mm3, respectively). There was
no difference in the rate of change in CD4 count post-
transfer according to nadir CD4 (interaction p = 0.48). In
the period prior to transfer, CD4 was lower on average in
females than males (−41 (−85, 2) cells/mm3; p = 0.06),
with no evidence for a difference in the rate of change in
CD4 by sex leading up to transition (p = 0.10). Although
prior to transfer CD4 was higher amongst those of non-
black ethnicity, this difference was non-significant (30
(−26, 86) cells/mm3; p = 0.30) and the rate of change
did not differ by ethnicity leading up to transition
(p = 0.28).
After transition, sex and ethnicity influenced the rate of
change in CD4; assuming independent effects (tested by
fitting a 4-level categorical variable, data not shown), CD4
declined among black males (−20 (−34, −5) cells/mm3 per
year post transition; p = 0.007), remained relatively stable
among black females (4 (−9, 18) cells/mm3 per year;
p = 0.51), and increased in white males (15 (−8, 37) cells/
mm3 per year; p = 0.22) and white females (39 (17,60)
cells/mm3 per year; p <0.001). After controlling for other
factors, overall CD4 counts were higher among people born
in later calendar years (14 (7, 22) cells/mm3 per later year),
and among those with suppressed viral load compared to
those with non-suppressed viral load (135 (125, 144) cells/
mm3). There was no association between CD4 count and
having been born abroad (p = 0.98). There was no evidence
for an interaction between time after transition and either
changing hospital at transfer (p = 0.23) or age at transfer
(p = 0.49), indicating that the rate of change in CD4 post-
transfer did not differ according to these factors.
Figure 2 shows the association between sex and CD4
slopes pre- and post-transfer, for modelled patients of
black ethnicity, born in the UK, with a nadir CD4 of 207
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Figure 1. CD4, viral load, age at transfer and death, and periods where no ART was prescribed, for 7 patients who died.
Judd A et al. Journal of the International AIDS Society 2017, 20(Suppl 3):21577
http://www.jiasociety.org/index.php/jias/article/view/21577 | http://dx.doi.org/10.7448/IAS.20.4.21577
74
cells/mm3 and an age at transfer to adult care of 17.5 years
(sample means), with no change of hospital at transfer. As
transition approached, slopes declined for both males and
females, and values were slightly lower for females.
However after transition, the decline in CD4 for males
continued, whilst for females it levelled off.
In paediatric care, 2% of CD4 measures followed a gap of
≥1 year since the previous measure; in adult care this went
up to 4%. There was no evidence for an effect of time since
last CD4 (< versus ≥1 year) (p = 0.13) and other model
coefficients changed very little when this term was
included.
Discussion
In our study of young people with HIV who had been
followed in our national paediatric cohort and subsequently
transferred to adult care, we identified 271 in a cohort of
adults attending outpatient clinics in the UK. The median
duration of follow-up in paediatric care was 12 years, and
adult care 3 years. A key advantage of our analysis was
having a complete national paediatric dataset, from which
we could link to patients attending adult clinics participat-
ing in UK CHIC.
We found no difference overall in the median CD4
count at either 12 months prior to leaving paediatric
care (465 cells/mm3) or 12 months after starting adult
care (460 cells/mm3), and the proportion with at least
one CD4 count <200 cells/mm3 in the 12 months pre-
and post-transfer was similar, at 21% and 23%, respec-
tively. This was much higher than a figure of 10% of
patients in UK CHIC overall with CD4 count <200 cells/
mm3 at any time in the 24 months prior to their last visit
in 2013 (S Jose, personal communication). Post-transfer
CD4 in our study was similar to a mean of 413 cells/
mm3 reported from a group of 46 young adults (7 with
perinatal HIV) aged 17–24 years, 48 weeks after starting
adult care in Chicago [28]. Another US study of 50 young
adults (19 with perinatal infection) with a median age of
28 years (older than our study), who were transitioning to
adult care in Baltimore, also reported no difference
between the CD4 count 12 months pre- and post-transfer
(median 347 cells/mm3 vs. 351 cells/mm3, respectively)
[29]. Interestingly, our findings were also not dissimilar
to a median CD4 change of 374 cells/mm3 at 48 weeks
from a baseline CD4 count of 170 cells/mm3 among 31
children and adolescents aged 9–19 years with perinatal
HIV infection starting ART for the first time in a commu-
nity-based ART programme in Cape Town, South Africa
[30]. Our CD4 findings suggest that post-transition, PHIV
are in worse health than other adults with HIV in the UK,
and reasons for this need further exploration. However,
the relatively short gap between the end of paediatric
care and the start of adult among these young people,
coupled with no difference in median CD4 count pre- and
post-transfer, is reassuring.
In our study although the proportion who were pre-
scribed ART increased after transition, this could in part
have been driven by a move towards universal ART in
recent years [31]. However, the proportion with two con-
secutive viral loads greater than 400 copies/mL or one viral
load >10,000 copies/mL in the 12 months pre- versus post-
transition did not change (47%, 52%). This is substantially
higher than the 10.2% with confirmed viral rebound
reported in the broader UK CHIC population of adults
starting ART for the first time [32]. Only around half of
young adults in our study had a continually suppressed
viral load pre- and post-transition, and the viral load trajec-
tories of those who died after transfer to adult care indi-
cated poor ART adherence. In the Netherlands, among 59
adolescents transitioning to adult care at median 19 years
of age, around 26% had two consecutive viral loads greater
than 400 copies/mL at 12 months post-transition, lower
than the proportion reported in our study, although over
Table 2. Key outcomes in paediatric and adult care (n = 271)
Paediatric care Adult care
n (%) /median [IQR] p value
Prescribed ART at last follow-up 200 (74%) 228 (84%) 0.001
CD4 count 12 months pre/post transfer (n = 204*) 465 [288,668] 460 [290,670] 0.38
CD4 < 200 cells/mm3 at least once in 12 months pre/post
transfer (n = 195*)
41 (21%) 45 (23%) 0.39
Two consecutive VL >400 copies/mL or one VL>10,000 copies/
mL in 12 months pre/post transfer for those on ART for at least
6 months (n = 131*)
37 (28%) 38 (29%) 0.85
Two consecutive VL >400 copies/mL or one VL>10,000 copies/
mL in 12 months pre/post transfer irrespective of ART status
(n = 196*)
92 (47%) 102 (52%) 0.12
IQR, interquartile range; ART, antiretroviral therapy*n = number with paediatric and adult care data.
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a shorter period of follow-up [33]. In the Baltimore study,
57% of young adults had a suppressed viral load (<400
copies/mL) at 12 months post-linkage to adult care [29].
These findings are in contrast to 76% viral suppression (<40
copies/mL) at last follow-up reported from 67 adolescents
engaged in a transition programme and transferred to adult
care in Northern Thailand [34].
Trends in CD4 count among adolescents during the
transition period varied by key socio-demographic and
clinical characteristics, as well as by whether patients
were pre- or post-transition. First, CD4 was higher both
pre- and post-transition in patients with higher nadir CD4
compared to lower nadir CD4. This trend is consistent
with current HIV treatment guidelines [35], and similar
findings have been reported in studies of adults with HIV
[36]; for example, among HIV seroconverters with viral
suppression, the absolute CD4 count attained after ART
start was highly dependent on both baseline and nadir
CD4 counts [37]. However, the CD4 count declined in
most groups of people as they approached transition,
with a greater rate of decline in those with a higher
nadir CD4 count. Declines in CD4 prior to transition
may be reflective of growing autonomy and worse adher-
ence during adolescence, and may themselves precipitate
transfer to adult care. Second, after transition, the CD4
count continued to decline in black males, but remained
constant in white males and black females, and increased
in white females. This finding warrants further investiga-
tion, especially considering that the majority of people in
our study were black African, and just under half of
participants were male. An analysis of adults attending
HIV clinics in England, Wales and Northern Ireland
reported that black African people had higher risk of
loss-to-follow-up than other ethnic groups [18]. In the
Netherlands study, there were no differences in virologi-
cal failure by gender [33], but other studies have not
reported any gender differences.
Third, CD4 was higher in patients with later birth years. The
majority of patients in our study were born pre-1996, so before
the combination therapy era, and although somemay not have
Table 3. Univariable and multivariable predictors of CD4 count change during transition to adult care
Univariablec Multivariable (n = 262b)
Predictor Coefficient 95% CI p value Coefficient 95% CI p value
Constant 154.0 65.6, 242.5 0.001
Main effects:a
Time before transition (per 1 year before transition) 9.2 1.7, 16.8 0.016 2.5 −9.5, 14.5 0.681
Time after transition (per 1 year after transition) −2.3 −12.7, 8.0 0.658 −19.6 −33.8, −5.4 0.007
Female −19.2 −72.4, 34.0 0.479 −41.1 −84.5, 2.3 0.064
Non-black ethnicity −80.6 −146.7, −14.4 0.017 29.7 −26.2, 85.6 0.298
Born abroad −3.5 −58.5, 51.6 0.902 −0.5 −43.7, 42.8 0.983
Year of birth (per 1 year increase) 20.0 11.5, 28.5 <0.001 13.7 6.7, 20.8 <0.001
Nadir CD4 cell count (per 10 cells/mm3 increase) 7.8 6.4, 9.3 <0.001 5.9 4.3, 7.4 <0.001
Viral suppression (time updated)
Non-suppressed, ≥400 copies/mL 0.0 0.0
Suppressed, <400 copies/mL 131.6 122.4, 140.7 134.5 125.2, 143.8
Missing 58.9 15.6, 102.3 <0.001 60.6 16.2, 105.1 <0.001
Interactions with time before transition (per 1 year):
Nadir CD4 cell count (cells/mm3)
0–99 - 0.0
100–199 10.1 −5.5, 25.5
200–299 12.5 −2.9, 27.9
300+ 27.7 9.0, 46.4 0.038
Interactions with time after transition (per 1 year):
Female 24.0 6.0, 41.9 0.009
Non-black ethnicity 34.1 11.6, 56.6 0.003
CI, confidence interval
aMain effects can be considered in isolation (i.e. ignoring interactions) when all other variables are equal to 0 (continuous) and notably at
transition or equal to the baseline category (categorical).
bNumber of participants.
cUnivariable models number of participants, n = 271 except for non-black ethnicity (n = 266), born abroad (n = 266), nadir CD4 cell count
(n = 269).
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presented for care until after 1996, this finding gives an indica-
tion of how improvements in treatment over time have
improved clinical outcomes, as shown elsewhere [21,38,39]. It
may also indicate improved transition planning in more recent
calendar year periods. Fourth, those with suppressed viral load
had substantially higher CD4 counts than those with non-sup-
pressed viral load, highlighting the continued importance of
adherence to ART in this population. Fifth, we found no effect
of age at transfer, or having changed hospital at transfer, on
CD4 after transition. In the Netherlands study, the average age
at transition was 18–19 years, and this age group was also
associated with the highest risk of virological failure [33]. The
lack of effect of age at transfer in our studymay be indicative of
clinics trying to ensure that transition planning is developmen-
tally appropriate and that the point of transfer is tailored to the
individual person’s needs, as recommended by UK transition
guidance, rather than occurring at or by a specific threshold as
is practice in other countries [22,29,33,40]. However half of our
cohort transitioned between the ages of 16 and 18 years, and
sowe do not know if outcomesmay have improved if transition
had been delayed until young people were in their 20 s.
Additionally, the finding that changing hospital at transfer did
not affect CD4 post-transition may again suggest a joined up
approach between paediatric and adult care where a change in
hospital does occur.
Our study has several limitations. The UK CHIC study does
not include all adults receiving care in the UK, and so we were
not able to link all young people who were documented in
CHIPS as having transferred to adult care. In turn we were
unable to measure loss-to-follow-up or mortality in those not
linked to UK CHIC, as those who had moved to adult care
could have been attending other non-UK CHIC clinics or could
have died prior to an adult care visit. We also did not focus on
any gaps between paediatric and adult care, because visit
frequency in the UK depends on where a patient is on their
treatment pathway as well as their CD4 level, and our patients
were an “in treatment” group by virtue of them being linked
between the two datasets. We are currently in the process of
gaining consent to follow all PHIV into adult care in the UK,
and plan subsequent analyses which can measure loss-to-
follow-up and care gaps. However mortality ascertainment
in UK CHIC was good, as data on deaths are linked with
national mortality registers and are also reported by partici-
pating clinics. Adherence data were not available, and so we
could only investigate the role of viral load as a predictor of
CD4 count change. Additionally, the UK CHIC dataset does not
have complete reporting of hospitalizations, a potentially
important measure of the success of transition. Research in
several disease areas has found poorer attendance and
increases in avoidable hospitalization post-transfer into adult
care, neither of which was measurable in our study [3,41].
Finally, the CHIPS and UK CHIC datasets are largely focussed
on clinical and biological markers of HIV, and thus we were
not able to consider the potential role of other factors, includ-
ing cognition andmental health. Poorer outcomesmay be due
to psychosocial issues as well as biological factors, including
cognitive and mental health issues [42–44], stigma and dis-
crimination [45], HIV disclosure [46] and parental loss [47].
This limits the clinical message of our findings, and further
exploration of the role of a wider set of factors is required
using in-depth cohort data.
Conclusions
Our findings suggest that CD4 in patients with perinatally
acquired HIV was already declining in the period before
transition to adult care, and that after transfer to adult
care there was some reversal in this trend in some groups.
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Figure 2. The association between sex and CD4 slopes over time for a hypothetical patient with the following characteristics: black
ethnicity, born in the UK in 1991, nadir CD4 of 207, transferred to adult care at 17.5 years (sample means), no hospital change at transfer.
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Post-transition, CD4 declined in black males, but remained
stable in black females, and increased in white males and
females; these findings are worrying and warrant further
monitoring. Furthermore, those with suppressed viral load
had higher CD4 counts, highlighting the ongoing need for
interventions to improve adherence during adolescence
and transition. Age at transfer and having changed hospital
at transfer had no effect on CD4 post-transition, but later
calendar year of birth was associated with higher CD4.
These findings lend support to improvements in transition
planning in the UK in recent years, the individual approach
to age at transition, and coordination of services across
paediatric and adult care. However, the much higher pro-
portion of young people with perinatally acquired HIV hav-
ing a CD4 < 200 cells/mm3 in adult care, compared to other
patients, is of great concern, and reasons for this require
further investigation.
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